TY - JOUR
T1 - What is the current status of ovarian suppression/ablation in women with premenopausal early-stage breast cancer?
AU - Higgins, Michaela J.
AU - Davidson, Nancy E.
PY - 2009/3
Y1 - 2009/3
N2 - The role of ovarian suppression/ablation (OS/OA) in premenopausal women with hormone receptor-positive breast cancer has been evolving for more than a century. It is clear that OS/OA is an effective adjuvant therapy for these women, but despite numerous studies enrolling thousands of women, many unanswered questions remain. In particular, a major question is whether additional benefit is gained with combination treatment comprising luteinizing hormone-releasing hormone (LH-RH) agonists and tamoxifen over tamoxifen alone. Ongoing trials also are assessing the coupling of aromatase inhibitors (traditionally contraindicated in these patients because of paradoxic stimulation of estrogen production) and LH-RH agonists. Any potential disease-free or overall survival advantage of combination treatment must be balanced against a possible increase in adverse effects and impairment of quality of life. This review focuses on new data regarding how to incorporate OS/OA into the rational treatment of this challenging patient population.
AB - The role of ovarian suppression/ablation (OS/OA) in premenopausal women with hormone receptor-positive breast cancer has been evolving for more than a century. It is clear that OS/OA is an effective adjuvant therapy for these women, but despite numerous studies enrolling thousands of women, many unanswered questions remain. In particular, a major question is whether additional benefit is gained with combination treatment comprising luteinizing hormone-releasing hormone (LH-RH) agonists and tamoxifen over tamoxifen alone. Ongoing trials also are assessing the coupling of aromatase inhibitors (traditionally contraindicated in these patients because of paradoxic stimulation of estrogen production) and LH-RH agonists. Any potential disease-free or overall survival advantage of combination treatment must be balanced against a possible increase in adverse effects and impairment of quality of life. This review focuses on new data regarding how to incorporate OS/OA into the rational treatment of this challenging patient population.
UR - http://www.scopus.com/inward/record.url?scp=77953461859&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77953461859&partnerID=8YFLogxK
U2 - 10.1007/s12609-009-0006-4
DO - 10.1007/s12609-009-0006-4
M3 - Review article
AN - SCOPUS:77953461859
SN - 1943-4588
VL - 1
SP - 42
EP - 47
JO - Current Breast Cancer Reports
JF - Current Breast Cancer Reports
IS - 1
ER -